Answers are grounded in this paper and cite their sources.
There exists a dearth of research concerning non-small cell lung cancer (NSCLC) patients experiencing overall progressive disease concomitant with shrinking lesions after immunotherapy. This is a special type of mixed response. We aim to evaluate the clinical characteristics and treatment options of these patients during immunotherapy.
No takes yet. Share an insight, caveat, or question.
Lv et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: